# To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

> **NCT04311515** · PHASE2 · TERMINATED · sponsor: **Samus Therapeutics, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **RADIATION:** Tau Positron emission tomography (PET)
- **RADIATION:** Fluorodeoxyglucose (FDG) Positron emission tomography (PET)
- **DIAGNOSTIC_TEST:** Cerebrospinal fluid (CSF) Biomarkers
- **DIAGNOSTIC_TEST:** Blood Biomarkers
- **BEHAVIORAL:** Rating Scales
- **DRUG:** PU-AD
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04311515
- **Lead sponsor:** Samus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-30
- **Primary completion:** 2020-09-09
- **Final completion:** 2022-11-15
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Samus Therapeutics company closure
- **Last updated:** 2022-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311515, "To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04311515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*